If the Danbury plant capacity and the patient demand ramp up quickly it won't take long. The company is in physical possession of $4-8 billion worth of raw insulin which they paid a fraction of that for. The COGS on the first $8-10 billion in Afrezza will be incredibly cheap. Even with half a billion in debt money should flow quickly to the bottom line.